Predicting response of ovarian cancer to paclitaxel treatment based on trend analysis of serum CA125.
Nekulova
Mirka
M
Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 65 Brno, The Czech Republic.
Pecen
Ladislav
L
Kalabova
Renata
R
Simickova
Marta
M
Topolcan
Ondrej
O
Pikner
Richard
R
Vondracek
Vladimir
V
Valik
Dalibor
D
D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000097:blood*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D017239:Paclitaxel / Q000627:therapeutic use*; D011379:Prognosis; D011446:Prospective Studies; D012016:Reference Values
D000972:Antineoplastic Agents, Phytogenic; D018394:CA-125 Antigen; D017239:Paclitaxel